PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A to Z of Drugs : D

Records returned : 150 (on 24 Nov 2024 at 10:03:00).

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
02.08.02
Dabigatran etexilate
Atrial fibrillation
Green (see narrative)
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
02.08.02
Dabigatran etexilate
Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE)
Blue
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NICE
Important
Specialist initiation and at least one month supply before transfer to primary care. Reserved for use where apixaban / rivaroxaban are not suitable
02.08.02
Dabigatran etexilate
VTE prevention post hip/knee replacement
Red
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
02.08.02
Dabigatran etexilate
VTE treatment and prevention (children)
N/A
Formulations :
  • Sachets (granules)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Dabrafenib
No Information Returned
Dacarbazine
No Information Returned
05.03.03
Daclatasvir
Hepatitis C
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
R
SA
NHSE
NICE
Daclizumab
No Information Returned
Daclizumab (Immunomodulating)
No Information Returned
Dacomitinib
No Information Returned
Dactinomycin
No Information Returned
05.01.07
Dalbavancin hydrochloride
Bacterial infection
Red
Formulations :
  • Infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Restricted Antimicrobial - requires Microbiology Specialist Approval.
02.08.01
Dalteparin sodium
VTE prophylaxis
Green
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
02.08.01
Dalteparin sodium
VTE treatment in patients unable to take oral anticoagulants
Blue
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Excluding obstetric and cancer patients. Specialist initiation and at least one month supply before transfer to primary care.
02.08.01
Dalteparin sodium
VTE prevention post hip/knee replacement
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
02.08.01
Dalteparin sodium
Pre-operative / bridging therapy
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
02.08.01
Danaparoid sodium
Heparin induced thrombocytopenia
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Heamatology only
Danazol
No Information Returned
10.02.02
15.01.08
Dantrolene sodium
Spasticity and muscle spasm
Green
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
10.02.02
15.01.08
Dantrolene sodium
Spasticity and muscle spasm
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
06.01.02
Dapagliflozin
Chronic Kidney Disease
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
If a patient with diabetes were on insulin and on multiple other treatments, a discussion with the specialist team may be prudent prior to dapagliflozin initiation.
06.01.02
Dapagliflozin
Heart failure
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Dapagliflozin/metformin
No Information Returned
Dapoxetine hydrochloride
No Information Returned
05.01.07
05.01.10
Dapsone
Bacterial infection
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
05.01.07
Daptomycin
Bacterial infection
Red
Formulations :
  • Infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
SA
Important
Restricted Antimicrobial - requires Microbiology Specialist Approval.
Darbepoetin alfa
No Information Returned
07.04.02
Darifenacin hydrobromide
Overactive bladder (adults)
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
Important
Switch to solifenacin recommended (if appropriate)
05.03.01
Darunavir
HIV infection
Red
Formulations :
  • Suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
NHSE
Important
Restricted Antimicrobial - requires GUM Specialist Approval
05.03.01
Darunavir/cobicistat
HIV infection
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
SA
NHSE
Important
Restricted Antimicrobial - requires GUM Specialist approval
05.03.03
Dasabuvir
Hepatitis C
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
R
SA
NHSE
NICE
Important
Requires approval from HCV national team for use
Dasatinib
No Information Returned
Daunorubicin
No Information Returned
Daunorubicin/cytarabine
No Information Returned
Debrisoquine sulfate
No Information Returned
Decitabine
No Information Returned
Deferasirox
No Information Returned
Deferiprone
No Information Returned
Deflazacort
No Information Returned
Degarelix
No Information Returned
05.01.09
Delamanid
Tuberculosis
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
05.01.03
Demeclocycline hydrochloride
Bacterial infection
Red
Formulations :
  • Capsules
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Restricted Use - for use when indicated by local trust antimicrobial guidelines or specialist microbiology recommendation.
06.06.02
Denosumab
Osteoporosis
Green (see narrative)
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Patients with a CKD of 4 or 5 and patients with a T-score of < -4.5 to remain under specialist care.
Depigmenting agents
No Information Returned
Dequalinium chloride
No Information Returned
Desferrioxamine mesilate
No Information Returned
03.04.01
Desloratadine
Allergic rhinitis
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Not a 1st-line option. Use cetirizine or loratadine 1st line.
03.04.01
Desloratadine
Allergic rhinitis
Non Formulary
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
Desmopressin acetate
No Information Returned
Desogestrel
No Information Returned
Desoximetasone
No Information Returned
04.06.00
11.04.01
12.01.01
Dexamethasone
Nausea and vomiting (chemotherapy induced)
Blue
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
On request from the specialist / Cancer Centre
04.06.00
11.04.01
12.01.01
Dexamethasone
Eye inflammation
Blue
Formulations :
  • Eye drops
  • Eye drops (preservative free, unit dose)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Short-term use only. Primary Care prescribing on specialist recommendation
04.06.00
11.04.01
12.01.01
Dexamethasone
Uveitis
Red
Formulations :
  • Intravitreal implant
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
Important
Ophthalmology specialists only
04.06.00
11.04.01
12.01.01
Dexamethasone
Retinal Vein Occlusion
Red
Formulations :
  • Intravitreal implant
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
Important
Ophthalmology specialists only
04.06.00
11.04.01
12.01.01
Dexamethasone
Diabetic macular oedema
Red
Formulations :
  • Intravitreal implant
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
Important
Ophthalmology specialists only
04.06.00
11.04.01
12.01.01
Dexamethasone
Ocular surgery
Red
Formulations :
  • Subconjunctival injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
04.06.00
11.04.01
12.01.01
Dexamethasone
Nausea and vomiting (post operative)
Red
Formulations :
  • Injection
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.06.00
11.04.01
12.01.01
Dexamethasone
Nausea and vomiting (chemotherapy induced)
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Dexamethasone isonicotinate
No Information Returned
06.03.02
10.01.02
Dexamethasone phosphate
Soft tissue and joint disorders
Green
Formulations :
  • Intra-articular injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Dexamethasone sodium metasulphobenzoate
No Information Returned
Dexamethasone sodium phosphate
No Information Returned
11.04.01
Dexamethasone with hypromellose, neomycin and polymyxin B
Eye inflammation and bacterial infection
Blue
Formulations :
  • Eye drops
  • Eye ointment
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Short-term use only. Primary Care prescribing on specialist recommendation.
11.04.01
Dexamethasone with tobramycin
Eye inflammation and bacterial infection
Red
Formulations :
  • Eye drops
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Short term use. GPs may prescribe a further supply to enable patients to complete their post-operative course.
04.04.00
Dexamfetamine sulfate
Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs
Amber
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
Dexibuprofen
No Information Returned
Dexketoprofen
No Information Returned
Dexmethylphenidate hydrochloride
No Information Returned
Dexpanthenol
No Information Returned
Dexrazoxane
No Information Returned
Dextromethorphan hydrobrom compound prepartions
No Information Returned
Dextromethorphan hydrobromide
No Information Returned
Dextromoramide tartrate
No Information Returned
Dextropropoxyphene
No Information Returned
03.09.01
04.07.02
Diamorphine hydrochloride
Pain
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
CD
Important
Limited stock - restrictions apply. Contact Pharmacy. Safety alert for High Dose
Diamorphine hydrochloride (Systemic)
No Information Returned
04.01.02
04.08.02
10.02.02
Diazepam
Spasticity and muscle spasm
Green
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.01.02
04.08.02
10.02.02
Diazepam
Status epilepticus
Green
Formulations :
  • Rectal solution
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.01.02
04.08.02
10.02.02
Diazepam
Spasticity and muscle spasm
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
04.01.02
04.08.02
10.02.02
Diazepam
Status epilepticus
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
02.05.01
06.01.04
Diazoxide
Hypertension in children
Red
Formulations :
  • Oral suspension
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
U
Important
Unlicensed. RSCH only for use on SCBU.
Dibasic potassium phosphate
No Information Returned
Dibrompropamidine isetionate
No Information Returned
Dichlorobenzyl alcohol
No Information Returned
Dichlorobenzyl alcohol/amylmetacresol
No Information Returned
Diclofenac diethyl
No Information Returned
10.01.01
Diclofenac potassium
Pain & inflammation - musculoskeletal
Non Formulary
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Diclofenac sod
No Information Returned
10.01.01
10.03.02
11.08.02
13.08.01
Diclofenac sodium
Pain & inflammation - musculoskeletal
Green
Formulations :
  • Suppositories
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
10.01.01
10.03.02
11.08.02
13.08.01
Diclofenac sodium
Osteoarthritis
Green (see narrative)
Formulations :
  • Gel
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
1%, 1.16% gels. Diclofenac gel is the most costly option in primary care. Consider a lower cost alternative e.g. ibuprofen 5% gel or piroxicam 0.5% gel.
10.01.01
10.03.02
11.08.02
13.08.01
Diclofenac sodium
Pain & inflammation - musculoskeletal
Green (see narrative)
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Restricted to use when oral NSAIDs are not an option.
10.01.01
10.03.02
11.08.02
13.08.01
Diclofenac sodium
Pain & inflammation - musculoskeletal
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Ibuprofen or naproxen are the preferred NSAIDS. Diclofenac for use if 1st-line options are ineffective / not tolerated. Restriced at Trusts to Rheumatology only.
10.01.01
10.03.02
11.08.02
13.08.01
Diclofenac sodium
Postoperative pain and inflammation (eye)
Blue
Formulations :
  • Eye drops
  • Eye drops (preservative free, unit dose)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Initiation by specialist team. Duration of treatment to be clarified if subsequent prescriptions are requested from primary care.
10.01.01
10.03.02
11.08.02
13.08.01
Diclofenac sodium
Pain & inflammation - musculoskeletal
Non Formulary
Formulations :
  • Modified release capsules
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
Important
Ibuprofen or naproxen are the preferred NSAIDS. Standard release diclofenac may be considered if 1st-line NSAIDs are ineffective / not tolerated.
10.01.01
Diclofenac sodium with misoprostol
Pain & inflammation - musculoskeletal
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
Dicobalt edetate
No Information Returned
01.02.00
Dicycloverine hydrochloride
Muscle spasm
Non Formulary
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Dicycloverine hydrochloride compound preparations
No Information Returned
05.03.01
Didanosine
HIV infection
Red
Formulations :
  • Dispersible tablets
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
NHSE
Important
Restricted Antimicrobial - requires GUM Specialist approval
Dienogest
No Information Returned
Diethylamine salicylate
No Information Returned
Diethylstilbestrol
No Information Returned
Diflucortolone valerate
No Information Returned
Diflunisal
No Information Returned
Digitoxin
No Information Returned
02.01.01
Digoxin
Arrhythmias
Green
Formulations :
  • Elixir
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
ONE 62.5mcg tablet is equivalent to 50mcg (1ml) of elixir
02.01.01
Digoxin
Heart failure
Green
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
ONE 62.5microgram tablet is approximately equivalent to 50microgram (1mL) elixir
02.01.01
Digoxin
Arrhythmias
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
02.01.01
Digoxin antibody
Digoxin toxicity
Red
Formulations :
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.07.02
Dihydrocodeine tartrate
Pain
Green
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
CD
04.07.02
Dihydrocodeine tartrate
Pain
Green (see narrative)
Formulations :
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
CD
Important
Consider use if standard release tablets are not tolerated or compliance is an issue.
Dihydrotachysterol
No Information Returned
Diloxanide furoate
No Information Returned
01.07.01
01.07.04
02.06.02
Diltiazem hydrochloride
Angina
Green
Formulations :
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Prescribe by BRAND
Tildiem Retard (TWICE daily) are the lowest cost brand in Primary Care for patients requiring a tablet formulation.
01.07.01
01.07.04
02.06.02
Diltiazem hydrochloride
Angina
Green
Formulations :
  • Modified release capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Prescribe by BRAND
Angitil SR capsules (TWICE daily) or Zemtard XL or Slozem (ONCE daily) are the lowest cost brands for Primary Care.
01.07.01
01.07.04
02.06.02
Diltiazem hydrochloride
Hypertension
Green
Formulations :
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Prescribe by BRAND
Tildiem Retard (TWICE daily) are the lowest cost brand in Primary Care for patients requiring a tablet formulation.
01.07.01
01.07.04
02.06.02
Diltiazem hydrochloride
Hypertension
Green
Formulations :
  • Modified release capsules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Prescribe by BRAND
Angitil SR capsules (TWICE daily) or Zemtard XL or Slozem (ONCE daily) are the lowest cost brands for Primary Care.
01.07.01
01.07.04
02.06.02
Diltiazem hydrochloride
Anal fissures
Green (see narrative)
Formulations :
  • Cream
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
U
Important
2nd-line where patient has not tolerated GTN or this has been ineffective. Use 2% ointment in preference to cream (unless ointment unavailable)
01.07.01
01.07.04
02.06.02
Diltiazem hydrochloride
Anal fissures
Green (see narrative)
Formulations :
  • Ointment
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
2nd-line where patient has not tolerated GTN or this has been ineffective.
Dimenhydrinate
No Information Returned
Dimenhydrinate/cinnarizine
No Information Returned
Dimercaprol
No Information Returned
Dimethyl fumar
No Information Returned
Dimethyl sulfoxide
No Information Returned
Dimeticone (Barrier)
No Information Returned
Dimeticone (Parasiticidal)
No Information Returned
07.01.01
Dinoprostone
Induction of labour
Red
Formulations :
  • Injection
  • Pessaries
  • Vaginal gel
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
07.01.01
Dinoprostone
Patent ductus arteriosus
Red
Formulations :
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Diosmin/hesperidin
No Information Returned
Diphenhydramine hydrochloride
No Information Returned
Diphenhydramine hydrochloride/pholcodine
No Information Returned
Diphtheria
No Information Returned
Dipipanone hydrochloride
No Information Returned
Dipivefrine hydrochloride
No Information Returned
02.09.00
Dipyridamole
Stroke/TIA
Green (see narrative)
Formulations :
  • Modified release capsules
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Not 1st-line. Alternative to clopidogrel and aspirin
02.09.00
Dipyridamole
Thromboembolism prophylaxis
Blue
Formulations :
  • Modified release capsules
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Dipyridamole and aspirin
No Information Returned
11.08.02
Disodium edetate
Band keratopathy / corneal chelations
Red
Formulations :
  • Eye drops
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
U
Important
0.37% eye drops (unlicensed)
Disodium folinate
No Information Returned
02.03.02
Disopyramide
Arrhythmias
Blue
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Specialist initiation and at least one month supply before transfer to primary care
02.03.02
Disopyramide
Arrhythmias
Blue
Formulations :
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Specialist initiation and at least one month supply before transfer to primary care
Disopyramide phosphate
No Information Returned
Distigmine bromide
No Information Returned
Disulfiram
No Information Returned
Dithranol
No Information Returned
02.07.01
Dobutamine hydrochloride
Inotropic support
Red
Formulations :
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Docetaxel
No Information Returned
01.06.02
Docusate sodium
Constipation
Green
Formulations :
  • Capsules
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
01.06.02
Docusate sodium
Constipation
Green
Formulations :
  • Enema
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Dolasetron mesilate
No Information Returned
05.03.01
Dolutegravir
HIV infection
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
SA
NHSE
Important
Restricted Antimicrobial - requires GUM Specialist approval
Dolutegravir/lamivudine
No Information Returned
Dolutegravir/rilpivirine
No Information Returned
04.06.00
Domperidone
Nausea and vomiting (Parkinson's disease)
Green
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Un
04.06.00
Domperidone
Nausea and vomiting
Green (see narrative)
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Important
ADULTS and adolescents over 12 years or weighing 35kg or more. Use lowest effective dose for shortest possible duration (max 1 week)
04.06.00
Domperidone
Nausea and vomiting (pregnancy)
Green (see narrative)
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
R
SA
Un
Important
Safety alert and cardiac side-effects.
2nd line treatment option but should not be prescribed for longer than 7 days.
04.06.00
Domperidone
Nausea and vomiting (chemotherapy induced)
Blue
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Off-label use. On request from the specialist / Cancer Centre
04.06.00
Domperidone
Gastroparesis
Red
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Refer to MHRA cardiac safety alerts. Off label use.
04.06.00
Domperidone
Dyspepsia
Red
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Refer to MHRA cardiac safety alerts. Off label use.
04.06.00
Domperidone
Gastro Oesophageal Reflux Disorder (GORD)
Red
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Refer to MHRA cardiac safety alerts. Off label use.
04.06.00
Domperidone
Gastric reflux in Neonates and Children
Red
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Refer to MHRA cardiac safety alerts. Off label use.
04.06.00
Domperidone
Parkinson's Disease (apomorphine pre-treatment)
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
04.06.00
Domperidone
Lactation stimulation
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Un
04.06.00
Domperidone
Nausea and vomiting
Red
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Important
CHILDREN under 12 years: MHRA safet alert, In children younger than 12 years or patients weighing less than 35kg - restricted to secondary care for a duration of less than 1 week
04.11.00
Donepezil hydrochloride
Multiple sclerosis
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
02.07.01
Dopamine hydrochloride
Cardiogenic shock
Red
Formulations :
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Dopexamine hydrochloride
No Information Returned
Doravirine
No Information Returned
Doripenem
No Information Returned
Dornase alfa
No Information Returned
11.06.00
Dorzolamide
Glaucoma / ocular hypertension
Blue
Formulations :
  • Eye drops
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Prescribe generically. Initiation by specialist team before transfer of prescribing to primary care
Dorzolamide and timolol
No Information Returned
11.06.00
Dorzolamide with timolol
Glaucoma / ocular hypertension
Blue
Formulations :
  • Eye drops
  • Eye drops (preservative free, unit dose)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Prescribe generically. Initiation by specialist team before transfer of prescribing to primary care
04.03.01
04.07.03
Dosulepin hydrochloride
Pain (Neuropathic)
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
Un
Doxapram hydrochloride
No Information Returned
07.04.01
Doxazosin
Benign prostatic hyperplasia
Green
Formulations :
  • Immediate release tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Preferred
07.04.01
Doxazosin
Benign prostatic hyperplasia
Non Formulary
Formulations :
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
Important
Use immediate release tablets
02.05.04
Doxazosin mesilate
Hypertension
Green
Formulations :
  • Immediate release tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Step 4 of the hypertension pathway.
02.05.04
Doxazosin mesilate
Hypertension
Non Formulary
Formulations :
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
Important
Step 4 of the hypertension pathway.
Use immediate release tablets
Doxepin
No Information Returned
Doxepin hydrochloride
No Information Returned
Doxorubicin hydrochloride
No Information Returned
05.01.03
Doxycycline hyclate
Bacterial infection
Green
Formulations :
  • Capsules
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Follow local guidelines on the use of antimicrobials.
Doxycycline monohydrate
No Information Returned
04.06.00
Doxylamine succinate/pyridoxine hydrochloride
Nausea and vomiting (pregnancy)
Green (see narrative)
Formulations :
  • Gastro-resistant tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Not a preferred 1st-line option. Use only after failure of at least one established 1st-line treatment options
Dried factor IX fraction
No Information Returned
Dried factor VIII fraction
No Information Returned
Dried factor XIII fraction
No Information Returned
Dronabinol/cannabidiol
No Information Returned
02.03.02
Dronedarone hydrochloride
Atrial fibrillation
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Cardiology only
04.02.01
04.06.00
Droperidol
Nausea and vomiting (post operative)
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Drotrecogin alfa
No Information Returned
Dulaglutide
No Information Returned
04.07.03
Duloxetine
Pain (Neuropathic)
Green
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Licensed only for diabetic peripheral neuropathic pain but also recommended as per NICE CG173 (off- label indication) as a treatment option in neuropathic pain.
07.04.02
Duloxetine hydrochloride
Stress incontinence
Green
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Dutasteride
No Information Returned
Dydrogesterone
No Information Returned
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More